Daiichi Sankyo is a global pharmaceutical company with a mission to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals. The company focuses on the development of novel therapies for patients with cardiovascular-metabolic diseases, oncology, and other areas of unmet medical need.

Daiichi Sankyo

LégiaPark is an economic activity center dedicated to hosting companies active in life sciences. It provides a suitable environment for research, production, or commercialization activities.

LégiaPark

VIRTRIS is a health data pioneer based in Seoul, South Korea, specializing in health data integration and analysis with the goal to accelerate drug discovery and approval.

VIRTRIS

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. 

For all other inquiries about Daiichi Sankyo such as products or careers, please visit our website www.daiichisankyo.com.

Please see below for global employment opportunities:

Daiichi Sankyo Europe: http://linkd.in/1C7vu7Z

Daiichi Sankyo Inc: http://linkd.in/1aDztT4

Daiichi Sankyo Spain: http://linkd.in/1DUavKt

Daiichi Sankyo Germany: http://linkd.in/1GZA11G

Daiichi Sankyo UK: http://linkd.in/1FwcGTo

Daiichi Sankyo Switzerland: http://linkd.in/1GZA3GR

Daiichi Sankyo France: http://linkd.in/1yPOAhu

Daiichi Sankyo Brazil: http://linkd.in/1CMnnQO

Daiichi Sankyo Ireland: http://linkd.in/1GZAbX2

Dr. Jokichi Takamine, the first president of Daiichi Sankyo predecessor company, Sankyo Co., Ltd., has been named as one of the six 2024 Historical Inductees in the National Inventors Hall of Fame in the United States.
 
Born in Japan in 1854, Dr. Takamine, was a visionary scientist, who counts the first successful crystallization of adrenaline among his many achievements. 

He was also a passionate inventor, turning a revolutionary process for brewing whisky with malted rice into the basis for developing the digestive enzyme product, Taka-Diastase, which became popular worldwide. #DrJokichiTakamine #DShistory
 
Click to learn more about Dr. Takamine’s induction into the US National Inventors Hall of Fame.
 
Passion for Innovation. Compassion for Patients.®

Daiichi Sankyo has been selected for the fourth year in row to CDP’s A List of companies for transparency and performance leadership in our corporate sustainability efforts to fight climate change.
 
CDP is a “not-for-profit charity that runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impacts,” and the CDP’s A List is comprised of more than 330 companies worldwide that are “leading the way in environmental transparency and performance on climate change, deforestation and water security.”
 
According to CDP, it holds the largest environmental database in the world and every year scores around 15,000 companies on their “climate change, forests and water security disclosures.”
 
Click to learn more about how Daiichi Sankyo is contributing to the realization of a decarbonized society by reducing CO2 emissions and increasing our utilization of renewable power. #CDPAList #sustainability 
 
Passion for Innovation. Compassion for Patients.®

Those living with cancer are faced with multiple barriers when navigating their diagnoses, which is why we’re joining the Union for International Cancer Control (UICC)’s call to help #CloseTheCareGap. 

This #WorldCancerDay, hear from our leaders throughout the world on how we are taking action to bridge those gap.

Passion for Innovation. Compassion for Patients.®

Daiichi Sankyo Europe GmbH’s Manuel Reiberg took advantage of a unique opportunity to move to Japan for a leadership position in our Tokyo headquarters.
 
With 20 years of experience in DS, having worked in Germany, Austria, and the UK, Manuel was excited about the prospect to take on an international assignment, living and working in Japan.
 
Click to learn how Manuel, and his family, are on an “inspiring journey” in the megacity of Tokyo. #daiichisankyo, #onedaiichisankyo
 
Passion for Innovation. Compassion for Patients.®

“Whenever you talk about patients, you should actually talk to patients because we have something important to say. Sit and talk with me because this is about my life.”
 
After being diagnosed with breast cancer in 2004 at the age of 34, Eva Schumacher-Wulf created a magazine called “Mamma Mia!” to provide women with breast cancer information to talk about scientific advances in an easy-to-understand way, enabling cancer patients to know and exercise their own options. This print and online platform now has a quarterly circulation of 20,000.
 
Eva openly and publicly advocates for patients' rights and interests despite having been diagnosed with breast cancer, experiencing and surviving countless treatments, coping with the ups and downs of good news and bad news, and raising two children.
 
Click to learn more about Eva’s patient journey and her passion as an advocate for incorporating the voice of the patient in drug development.

Passion for Innovation. Compassion for Patients.®

What do you usually do with the plastic packaging that your medicines come in? Did you know that “PTP” (press-through-package) packaging in which tablet medicines are wrapped can be recycled?
 
Daiichi Sankyo’s over-the-counter medicine company, Daiichi Sankyo Healthcare, together with the Japan affiliate of TerraCycle and with the cooperation of the City of Yokohama initiated the first Medicine Sheet Recycling Program in Japan that involved consumer participation.
 
For one year, from October 2022 to September 2023, special collection boxes were installed at pharmacies, drug stores, hospitals, and other public facilities, such as ward offices, in certain areas of Yokohama with the intention of separating collected medicine sheets into plastic and aluminum, and then turning them into recycled products.
 
The program’s original goal was to have 30 collection sites and collect 100,000 pieces, but due to an enthusiastic response from the citizens of Yokohama, with more than half saying (in a post-program survey) that they had participated, the number of sites was eventually increased to 60 and the amount collected reached the equivalent of 1.08 million pieces (1,077 kg), which was approximately double the revised target!
 
Daiichi Sankyo Healthcare received many positive comments from the pharmacies and facilities that served as collection sites, and some of them even called or wrote us to share their satisfaction with the program. 
 
The next goal is a full-scale rollout of the program in Yokohama, and we hope to expand the collection sites across their city to approximately 100 by March 2024. We also want to consider expanding the program nationwide.
 
Since medicine sheets are difficult to separate because the type and composition of plastic materials differ for each drug, consuming extra energy to recycle them, we also aim to develop an efficient recycling method by the end of 2024 and will be looking in more detail into the kinds of products which can be made from recycled plastic.
 
As part of our Sustainability commitment to contribute to the local community as a good corporate citizen, Daiichi Sankyo will continue to promote the full-scale rollout of the Medicine Sheet Recycling Program to spread awareness of medicine sheet recycling and establish a sustainable system in which to do it. 
 
Passion for Innovation. Compassion for Patients.®

We’re excited to take part in the first ever Ducky Challenge in Japan hosted by Mizuho to reduce our CO2 emissions and build climate awareness in our company as part of our “Daiichi Sankyo Sustainability Week” activities. #sustainabilty 
 
Sustainability Week is designed to help our stakeholders get a deeper understanding of what we are doing to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” #sustainability #sustainabilityweek
 
Passion for Innovation. Compassion for Patients.®

Daiichi Sankyo pursues #sustainability for our company and society through the creation of innovative pharmaceutical products that leverage our strengths in science and technology, 
 
In this video entitled, "Daiichi Sankyo Group's Approach to Sustainability," we outline our commitment to ESG management and initiatives aimed at realizing our Purpose of “contributing to the enrichment of quality of life around the world” through fulfillment of our 2030 Vision to transform into an “innovative global healthcare company contributing to the sustainable development of society. 
 
Click to watch and learn more about how we approach sustainability and what we have been tackling to contribute to the enrichment of quality of life around the world. 
 
Passion for Innovation. Compassion for Patients.®

Daiichi Sankyo’s Global Head of Oncology Clinical Development, Mark Rutstein, always knew he wanted to help people.
 
Inspired during his undergraduate studies by his sister, who was training in surgical oncology, Mark searched out volunteer work at hospitals, which in turn drew him from pre-law to the field of medicine.
 
Following medical school and a residency where he gained extensive experience treating patients with cancer, Mark’s interest shifted again, and he decided to attend business school while also continuing his work as a doctor.
 
The understanding of business and healthcare he gained during his studies led him to his first position in the pharmaceutical industry, and eventually years later, to overseeing global clinical development of oncology at Daiichi Sankyo. #daiichisankyo  #science&technology #DSOBU
 
Click to learn more about Mark’s remarkable journey of helping people “through the intersection of medicine and business.”
 
Passion for Innovation. Compassion for Patients.®

Daiichi Sankyo Europe’s Heidi Anthoni took advantage of a unique opportunity to move to Japan for a position in our Tokyo headquarters.

Now in her eighth year with the company, Heidi was excited for the chance to have an international assignment in medical affairs, living and working in Japan.
 
Click to learn how Heidi, and her family, are “navigating a new life and career” in the megacity of Tokyo. #daiichisankyo #onedaiichisankyo

https://lnkd.in/gkd6qick

Passion for Innovation. Compassion for Patients.®

Metric
Company Name	Daiichi Sankyo	LégiaPark	VIRTRIS
Symbol
MSH ID	COM:DAIICHISANKYO	BE:LEGIAPARK	COM:VIRTRIS
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Commercial & Professional Services	Healthcare & Health Services
Industry	Pharmaceuticals	Life Sciences	Biotechnology
Country	JP	BE	KR
Stage
Employee Count	827
Website	daiichisankyo.com	legiapark.be	virtris.com
LinkedIn	daiichi-sankyo-co-ltd-	l%C3%A9giapark	virtus
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:DAIICHISANKYO

Daiichi Sankyo

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue